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Abstract
The choice of induction agent for endotracheal intubation can have
significant downstream effects, especially in critically ill patients. In
a retrospective study, Ray and McKeown found that the choice of
induction agent had no significant effect on use of vasoactive
medications, corticosteroids, or mortality. Given the heated debate
regarding corticosteroids in septic shock and the role that
etomidate may play in leading to adrenal insufficiency, enthusiasm
for etomidate as an induction agent should be tempered by its
possible, significant side effects in these critically ill patients.
The period of induction of anesthesia in patients with sepsis
continues to carry inherent risk for further compromise in
these critically ill individuals. Extreme caution must be exer-
cised in choosing an induction agent to perform endotracheal
intubation in these unstable patients. In this issue of Critical
Care, Ray and McKeown [1] report a retrospective review in
which they examine the influence of induction agent on
further utilization of vasoactive medications, corticosteroids,
and mortality, with a particular focus on etomidate.
Etomidate is known to cause adrenal suppression, both after
a single dose and with prolonged infusion [2,3]. The clinical
significance of this drug effect continues to be debated, but
etomidate does not carry the significant acute hemodynamic
effects of other induction agents [4]. This makes it a common
choice to facilitate endotracheal intubation in intensive care
unit (ICU) patients, particularly those with hypotension or who
are at risk for hypotension during airway management. In this
retrospective study, the choice of induction agent (etomidate,
propofol, thiopental, or ‘other’ [midazolam, ketamine, or
fentanyl]) was not associated with differences in or doses of
vasoactive drug, duration of vasoactive drug infusion, or time
from administration of induction drug to commencement of
vasoactive drug infusion. Use of etomidate resulted in less
frequent need for vasopressor administration at the time of
induction. The use of etomidate did not alter the use of
corticosteroids or mortality. However, patients who received
etomidate and corticosteroids had higher mortality than did
those who received etomidate alone. Even though the
patients who received etomidate were sicker than those who
received other agents, this raises the possibility that the
adrenal suppression caused by etomidate is not as reversible
as was once thought [5].
Corticosteroids and relative adrenal insufficiency in sepsis
continue to provide areas of intense debate for practitioners
of critical care. The precise roles played by total cortisol
levels, free cortisol levels [6], and the adrenocorticotropic
hormone stimulation test in defining relative adrenal
insufficiency in sepsis are not well solidified. For example, in
the study conducted by Ray and McKeown [1], patients were
empirically given corticosteroids for vasopressor-refractory
shock and cortisol levels were not measured, and neither
were adrenocorticotropic hormone stimulation tests
performed. This is in contrast to multiple studies that utilized
various definitions of relative adrenal insufficiency to guide
the use of corticosteroids [7]. The role of etomidate is an
important factor in this debate. In a recent retrospective study
associated with the Corticus group [8], etomidate was
associated with increased risk for death by univariate analysis
(odds ratio 1.53, 95% confidence interval 1.06 to 2.26) but
not by multivariate analysis (odds ratio 1.82, 95% confidence
interval 0.52 to 6.36). The univariate significance coupled
with nonsignificance but wide confidence intervals by
multivariate analysis suggests that larger sample sizes may be
needed to address this issue definitively. These data, which
conflict with the findings reported by Ray and McKeown [1],
raise concerns regarding the safe use of etomidate in septic
patients as well as its influence on the findings of future trials
conducted to elucidate the role of corticosteroids in treating
septic shock.
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Despite ongoing controversy regarding the clinical importance
of etomidate-induced adrenal suppression, this medication
does provide significant short-term benefits. Patients with
septic shock uniformly have hemodynamic or respiratory
compromise, and commonly both. The institution of
mechanical ventilation is a necessary therapy in most of these
patients and should be performed as safely, and quickly, as
possible. The placement of the endotracheal tube should be
performed by relatively experienced hands and in a setting (in
terms of both location and anesthesia equipment and
personnel) that is best for the patient [9]. The use of other
induction agents, such as propofol or thiopental, can result in
further hemodynamic compromise during the initiation of
mechanical ventilation, which is not an insignificant problem in
patients who are in shock [10]. The ability of etomidate to
cause less hemodynamic instability in the peri-intubation
period cannot be ignored. Although the debate regarding the
adrenal axis in sepsis continues, the need for respiratory
support in patients in shock is rarely questioned. Mechanical
ventilation is a necessary supportive therapy for many patients
in septic shock, and providing an environment in which the
operator can place an endotracheal tube as efficiently as
possible with avoidance of further significant hemodynamic or
respiratory compromise is not to be underestimated. The use
of opiates (for instance, fentanyl), topical local anesthetics
only, or no agent can be considered in a subgroup of ICU
patients who require endotracheal intubation.
The limitations of the study by Ray and McKeown [1] must be
considered. The authors note that one limitation is the
retrospective nature of their data analysis. Despite the fact
that a reasonably large number of patients was evaluated
(n = 159), no power calculation was reported in this study,
and the possibility of a type II error must be considered. This
is especially pertinent given the ‘mixed’ results of other work,
such as the retrospective Corticus study mentioned above
[8]. We can thank Drs Ray and McKeown for adding
important information to the literature regarding the use of
etomidate in the ICU. The conclusion regarding the safety of
this drug for use in facilitating endotracheal intubation should
be tempered by the recognition that more data are needed.
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